News & Events about Lava Therapeutics Nv.
UTRECHT, The Netherlands and PHILADELPHIA, Jan. 23, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary Gammabody platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that...
Peter A. Kiener, DPhil and Mary E. Wadlinger to Join LAVA BoardUTRECHT, The Netherlands and PHILADELPHIA, Jan. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody platform of bispecific gamma ...
UTRECHT, The Netherlands and PHILADELPHIA, Jan. 03, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today ...
Poster presentation to include initial data from subcutaneous administration and updates on intravenous dosing-cohortsUTRECHT, The Netherlands and PHILADELPHIA, Pa., Dec. 10, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on ...
Ticker Report
2 months ago
LAVA Therapeutics (NASDAQ:LVTX Get Rating)s stock had its buy rating reiterated by equities research analysts at JMP Securities in a report released on Tuesday, Stock Target Advisor reports. They currently have a $6.00 price target on the stock. JMP Securities ...